EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Syra Health Corp. Class A (SYRA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Syra Health Corp. Class A $0.13, price $0.87, upside -85.3%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US87168W2035

SH Syra Health Corp. Class A logo Thin data Sep 23, 2026

Syra Health Corp. Class A

SYRA · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.1275 · Strongly overvalued (−85%)
!Quality 44/100
!Expensive Growth (revenue 3y +8.8 %/yr)
!Thin margins · 1.6% net margin (TTM)
!negative free cash flow
!Trails peers (2/10)
!Narrow moat 29/100
!Evidence only low, so the estimate is less certain
!Weak on past: 21 out of 100
Watch Syra Health Corp. Class A Common Stock for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.85 $0.0521 Fair Value $0.1275 Sep 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

36‑month range $0.0521 – $4.85 · fair‑value band $0.0850 – $0.1615 · the $0.8700 price screens above the $0.1275 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Syra Health Corp. Class A Common Stock in your weekly email

Every Wednesday you see whether Syra Health Corp. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States.

Show more

Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States. The company offers Syrenity, a behavioral and mental health application that identifies and prevents the progression of negative factors that can influence individuals' mental health by offering targeted assignments, education, and monitoring symptoms, as well as providing interventions, such as cognitive behavioral therapy and mindfulness techniques; digital health products, including SyraBot, a chatbot to foster connectivity and engagement throughout individuals' care journeys offering members access to necessary information via its AI-powered customer support chat system; and CarePlus, an electronic medical records solution for small to mid-sized healthcare organizations. It also provides analytics as a service, analytics as a service, epidemiology, and health equity analytics solutions. In addition, the company offers medical communications, patient education, and healthcare training; and recruits nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. The company was incorporated in 2020 and is headquartered in Carmel, Indiana.

Stock analysis

Syra Health Corp. Class A Common Stock (SYRA) currently trades at $0.8700, while our model-based Fair Value estimate is $0.1275, implying the stock looks roughly 582.1% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.0850 (bear) to $0.1615 (bull), the price of $0.8700 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Syra Health Corp. Class A Common Stock reported revenue of $7.2M in FY2025 versus $1.4M in FY2021, a compound +50.5%/yr. Reported net income was −$896K in FY2025.

Key figures

Market cap $11.8M · P/E ratio 84.9 · P/S ratio 1.51 · EPS (TTM) $0.0100 · Net margin −12.4% · Return on equity 5.2% · Return on assets (EBIT) −56.9% · Operating margin 10.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 1,350% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −85%, SYRA screens richer than that median.

Fair Value models

Bear $0.0850 Fair Value $0.1275 Bull $0.1615
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0073 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0800 $0.1000 $0.1500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.0800 $0.1000 $0.1500 51

Open the full fair value analysis →

Notify me when SYRA reaches fair value

Put SYRA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 46 · Market factors (momentum, volatility) 68

Profitability 40
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 56
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 91
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.2% (2021) → −12.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SYRA screens 582% overvalued. Compare with HCA Healthcare, Inc →

Compare Syra Health Corp. Class A Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −85% · Bottom 25%
Profitability
Return on equity (TTM) 5% · Below median
Return on assets 1% · Below median
Net margin (TTM) 2% · Below median
Operating margin (TTM) 11% · Above median
Growth and dividend
Revenue growth 23% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 84.9× · Priciest 25%
P/B 5.62× · Priciest 25%
P/S (TTM) 1.46× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)21 · sector 31
HEALTH (low debt)0 · sector 89
DIVIDEND (yield)0 · sector 42

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $438.12 $592.64 +35%
Fresenius SE FRE €45.57 €34.54 −24%
Dr. Sulaiman Al Habib Medical Services Group 4013 227.50 SAR 109.45 SAR −52%
IHH Healthcare Berhad, an investment holding company, 5225 8.00 MYR 4.87 MYR −39%
Tenet Healthcare Corporation THC $262.06 $399.58 +52%
DaVita Inc DVA $183.72 $255.97 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹9,069 ₹2,908 −68%
Fresenius Medical Care AG FME €39.30 €71.28 +81%
Aier Eye Hospital Group 300015 ¥8.07 ¥10.86 +35%
Encompass Health Corporation EHC $122.76 $96.51 −21%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Syra Health Corp. Class A Common Stock · Fair Value
$0.1275 −582%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Syra Health Corp. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/SYRA

Frequently asked questions

Is Syra Health Corp. Class A (SYRA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1275 versus a price of $0.8700, about −85% upside (overvalued).
What is the fair value of SYRA?
Our model-based fair value for Syra Health Corp. Class A Common Stock is $0.1275 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.8700.
What is the quality score of SYRA?
Syra Health Corp. Class A Common Stock has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Syra Health Corp. Class A (SYRA)?
Our model-based price target is the fair value of $0.1275 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.0850, optimistic scenario $0.1615. It is a calculation from audited fundamentals, not an analyst target.
What is the Syra Health Corp. Class A Common Stock stock forecast for 2026?
Our models put fair value at $0.1275, about −85% upside versus a price of $0.8700 (overvalued). Cautious scenario $0.0850, optimistic scenario $0.1615. The calculation is refreshed regularly with new filings.
What is the revenue of Syra Health Corp. Class A (SYRA)?
Syra Health Corp. Class A Common Stock reported trailing-twelve-month revenue of about $8.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Syra Health Corp. Class A (SYRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Syra Health Corp. Class A Common Stock it is $0.1275 per share (as of Sep 23, 2026), against a price of $0.8700. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Syra Health Corp. Class A Common Stock stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SYRA trades above its calculated fair value: price $0.8700, fair value $0.1275, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYRA?
No. The price is what the market pays today ($0.8700); the fair value is what the company's own numbers justify ($0.1275). For Syra Health Corp. Class A Common Stock the two are $0.7425 per share apart. That gap is exactly why we show both numbers side by side.
How much is Syra Health Corp. Class A Common Stock worth?
The market values Syra Health Corp. Class A Common Stock at about $11.8M (market capitalisation, as of Sep 23, 2026). Per share that is $0.8700; our models calculate a fair value of $0.1275 per share.
What do the bullish and bearish scenarios say about SYRA?
Our models span a range for Syra Health Corp. Class A Common Stock: cautious scenario $0.0850, base $0.1275, optimistic $0.1615 per share (as of Sep 23, 2026, price $0.8700). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SYRA?
Syra Health Corp. Class A Common Stock trades at a price-to-earnings ratio of 84.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1275 is built from several models across several years. Other multiples: P/B 5.6, P/S 1.5.
How solid is the balance sheet of Syra Health Corp. Class A (SYRA)?
Balance-sheet figures for Syra Health Corp. Class A Common Stock (as of Sep 23, 2026): return on equity 5.2%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is SYRA from its 52-week high?
Syra Health Corp. Class A Common Stock trades at $0.8700, about 17% below its 52-week high of $1.05 and 1,350% above the low of $0.0600 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1275 is for.
Which stocks are comparable to Syra Health Corp. Class A Common Stock?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Syra Health Corp. Class A Common Stock stock attractive at the current price?
The data as of Sep 23, 2026: price $0.8700, calculated fair value $0.1275 (−85%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYRA calculated?
We run Syra Health Corp. Class A Common Stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1275, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Syra Health Corp. Class A Common Stock itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Syra Health Corp. Class A (SYRA)?
The closing price on Sep 23, 2026 was $0.8700. Our model-based fair value is $0.1275, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Syra Health Corp. Class A Common Stock right now?
The price sits above even our optimistic bull case ($0.1615). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0850 to $0.1615) leaves room in how you read the outcome.

Key figures of Syra Health Corp. Class A Common Stock

How large is the market capitalisation of Syra Health Corp. Class A (SYRA)?
The market capitalisation of Syra Health Corp. Class A Common Stock is $11.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Syra Health Corp. Class A (SYRA)?
The price-to-sales ratio of Syra Health Corp. Class A Common Stock is 1.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Syra Health Corp. Class A (SYRA)?
Earnings per share at Syra Health Corp. Class A Common Stock are $0.0100 (price ÷ EPS = P/E 84.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Syra Health Corp. Class A (SYRA)?
The net margin of Syra Health Corp. Class A Common Stock is −12.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Syra Health Corp. Class A (SYRA)?
The return on equity (ROE) of Syra Health Corp. Class A Common Stock is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Syra Health Corp. Class A (SYRA)?
On an EBIT basis the return on assets of Syra Health Corp. Class A Common Stock is −56.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Syra Health Corp. Class A (SYRA)?
The operating margin of Syra Health Corp. Class A Common Stock is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Syra Health Corp. Class A (SYRA)?
Revenue at Syra Health Corp. Class A Common Stock is growing +23.0% versus a year earlier (3y avg +8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Syra Health Corp. Class A (SYRA) generate?
The free cash flow of Syra Health Corp. Class A Common Stock is −$448K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Syra Health Corp. Class A (SYRA) hold?
Syra Health Corp. Class A Common Stock holds more cash than debt, $1.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Syra Health Corp. Class A Common Stock in the live analysis

One click puts Syra Health Corp. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.